Ca 2 -Dependent Rapid Ca 2 Sensitization of Contraction in Arterial Smooth Muscle

Transcription

1 Ca 2 -Dependent Rapid Ca 2 Sensitization of Contraction in Arterial Smooth Muscle George J. Dimopoulos,* Shingo Semba,* Kazuyo Kitazawa, Masumi Eto, Toshio Kitazawa Abstract Ca 2 ion is a universal intracellular messenger that regulates numerous biological functions. In smooth muscle, Ca 2 with calmodulin activates myosin light chain (MLC) kinase to initiate a rapid MLC phosphorylation and contraction. To test the hypothesis that regulation of MLC phosphatase is involved in the rapid development of MLC phosphorylation and contraction during Ca 2 transient, we compared Ca 2 signal, MLC phosphorylation, and 2 modes of inhibition of MLC phosphatase, phosphorylation of CPI-17 Thr38 and MYPT1 Thr853, during 1 agonist induced contraction with/without various inhibitors in intact rabbit femoral artery. Phenylephrine rapidly induced CPI-17 phosphorylation from a negligible amount to a peak value of mol of Pi/mol within 7 seconds following stimulation, similar to the rapid time course of Ca 2 rise and MLC phosphorylation. This rapid CPI-17 phosphorylation was dramatically inhibited by either blocking Ca 2 release from the sarcoplasmic reticulum or by pretreatment with protein kinase C inhibitors, suggesting an involvement of Ca 2 -dependent protein kinase C. This was followed by a slow Ca 2 -independent and Rho-kinase/protein kinase C dependent phosphorylation of CPI-17. In contrast, MYPT1 phosphorylation had only a slow component that increased from at rest to the peak of mol of Pi/mol at 1 minute, similar to the time course of contraction. Thus, there are 2 components of the Ca 2 sensitization through inhibition of MLC phosphatase. Our results support the hypothesis that the initial rapid Ca 2 rise induces a rapid inhibition of MLC phosphatase coincident with the Ca 2 -induced MLC kinase activation to synergistically initiate a rapid MLC phosphorylation and contraction in arteries with abundant CPI-17 content. (Circ Res. 2007;100: ) Key Words: CPI-17 MYPT1 PKC Rho-kinase A wide range of excitatory agonists including 1 - adrenergic agonist activates both heterotrimeric G q and G 12/13 G proteins in smooth muscle following their bindings to G protein coupled receptors. 1 The former G protein further activates phospholipase C to hydrolyze plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP 2 ) and concurrently generates 2 signaling messengers: a water-soluble inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). The former messenger diffuses to the cytoplasm and binds to the IP 3 receptor channel in the sarcoplasmic reticulum (SR) membrane to induce Ca 2 release from the lumen. This Ca 2 triggers the rapid phasic component of contraction and myosin light chain (MLC) phosphorylation through activation of the Ca 2 /calmodulin-dependent MLC kinase (MLCK). Although Ca 2 influx is subsequently increased through opening of surface membrane Ca 2 channels, [Ca 2 ] i is not kept constant but rather transient and/or oscillates during the agonist stimulation. 2 The average MLC phosphorylation is also transient; however, the tonic component of the phosphorylation after the peak is maintained at higher levels than expected from the Ca 2 signal, as compared with that of high K stimulation, suggesting an increase in the Ca 2 sensitivity of MLC phosphorylation via the inhibition of MLC phosphatase (MLCP). 1,2 As a result, a relatively high level of MLC phosphorylation and contraction is achieved even at low MLCK activity under low [Ca 2 ] i during agonist-induced contraction. 3 The inhibition of MLCP thus appears to play as critical a role as the Ca 2 -dependent activation of MLCK in the maintenance of tonic contraction. MLCP is a holoenzyme composed of 3 subunits: a 38-kDa catalytic subunit ( isoform of type 1 protein phosphatase, PP1c ), a large 110- to 130-kDa regulatory subunit (MYPT1), and a small 20-kDa subunit. 4 MYPT1 is responsible for binding to and activation of PP1c and for targeting myosin. Two major signaling pathways have been proposed for the in situ inhibition of MLCP. One is the phosphorylation of MYPT1 at Thr696 and Thr853 via G 12/13 /RhoA/Rho-kinase pathway. 1 Recently, Hartshorne and colleagues 5 demonstrated these results, although conflicting with their previous finding 6 that the phosphorylation at not only Thr696 but also Thr853 equally suppresses the phosphatase activity. Several other kinases such as integrin-linked kinase (ILK), zipperinteracting protein kinase (ZIPK), p21-activated kinase (PAK), and dystrophia myotonica protein kinase (DMPK) Original received July 27, 2006; revision received November 15, 2006; accepted November 16, From the Boston Biomedical Research Institute (G.J.D., S.S., K.K., T.K.), Watertown, Mass; and Department of Physiology (M.E.), Jefferson Medical College, Philadelphia, Pa. *Both authors contributed equally to this work. Correspondence to Toshio Kitazawa, Boston Biomedical Research Institute, 64 Grove St, Watertown, MA Kitazawa@bbri.org 2007 American Heart Association, Inc. Circulation Research is available at DOI: /01.RES df 121

2 122 Circulation Research January 5/19, 2007 can also phosphorylate the Thr696 site. 1 However, the in situ phosphorylation at Thr696 in smooth muscle tissues and cultured cells is only minimally increased on G protein activation and not decreased by the Rho-kinase inhibitor Y-27632, which can significantly suppress agonist-induced Ca 2 sensitization of contraction and MLC phosphorylation. 7,8 On the other hand, Thr853 is a Rho-kinase specific site, and, in fact, the in situ phosphorylation is significantly increased in response to agonist stimulation via Rho-kinase pathway in smooth muscle tissues and cultured cells. 5,7 The second mechanism of MLCP inhibition is through phosphorylation of smooth muscle-specific MLCP inhibitor protein CPI Although there are multiple sites to be phosphorylated, the phosphorylation at only Thr38 increases the inhibitory effect of CPI-17 on MLCP by 1000-fold. 10 A major kinase for agonist-induced CPI-17 phosphorylation at Thr38 in smooth muscle tissues is protein kinase C (PKC), 9,11 which is activated by phospholipase C generation of DAG. Therefore, a potential signaling pathway through CPI-17 phosphorylation toward inhibition of MLCP is G q /phospholipase C /DAG/PKC/CPI-17/MLCP. Another possible pathway is through Rho-kinase induced phosphorylation of CPI- 17. This is based on the evidence that the Rho-kinase inhibitor reduces agonist-induced CPI-17 phosphorylation. 7,8,11 Furthermore, overexpression of constitutively active RhoA in cultured arterial smooth muscle cells increases CPI-17 phosphorylation. 12 Thus, multiple signaling pathways mediate the agonist-induced inhibition of MLCP via the phosphorylation of MYPT1 and CPI-17. Furthermore, expression ratios of CPI-17 relative to MYPT1 (ie, MLCP) largely vary, depending on the type of smooth muscle. 13 Thus, the Ca 2 - sensitizing signal transduction through phosphorylation of MYPT1 and CPI-17 depends on the tissue type. However, the kinetics of 2 phosphorylations, CPI-17 at Thr38 and MYPT1 at Thr853, on agonist stimulation have not been investigated in detail. We hypothesized that these 2 phosphorylations are activated in a specific time course on agonist stimulation. We therefore examined the temporal relationship among Ca 2, MLC phosphorylation, CPI-17 (Thr38) phosphorylation, MYPT1 (Thr853) phosphorylation, and contraction in response to the 1 agonist phenylephrine (PE) in rabbit femoral artery tissues and, furthermore, determined the effects of Ca 2 blockers, PKC inhibitors, and Rho-kinase inhibitors on these parameters. We also determined the stoichiometric amount of the in situ phosphorylation of CPI-17 and MYPT1. Our results reveal that, in addition to known Ca 2 -independent phosphorylation of CPI-17 and MYPT1, CPI-17 is Ca 2 - dependently phosphorylated by PKC as rapidly as MLCs are phosphorylated. The source of Ca 2 for the rapid phosphorylation is agonist-induced Ca 2 release from the sarcoplasmic reticulum (SR) but not Ca 2 influx from the extracellular space. Materials and Methods Tissue Preparation and Force Measurement All animal procedures were approved by the Animal Care and Use Committee of the Boston Biomedical Research Institute. Smooth muscle strips of rabbit femoral artery were prepared and mounted for force measurements and quick-freezing using liquid nitrogen cooled propane, as described previously in detail. 14 For more details, see the expanded Materials and Methods section in the online data supplement, available at Cytoplasmic Ca 2 Measurements The method for intracellular Ca 2 ([Ca 2 ] i ) measurement in the fura-2 loaded artery was essentially similar to that of Himpens et al. 15 See the online data supplement for more details. Measurement of MLC Phosphorylation In situ phosphorylation of MLC in muscle strips was measured using the 2D electrophoresis, as described previously. 14 See the online data supplement for more details. Antibodies and Western Blotting The antibodies used and Western blotting experiments have been described previously. 7,11 See the online data supplement for more details. Statistics Results are expressed as the means SEM of n experiments. Statistical significance was evaluated using ANOVA analysis. A level of P 0.05 was considered statistically significant. Results Time Course of PE-Induced Contraction and Phosphorylation of MLC, CPI-17, and MYPT1 in Rabbit Femoral Artery Figure 1A illustrates an example of the simultaneous measurements of Fura-2 ratio signal and isometric contraction in response to 50 mol/l PE, with a clear indication of the Ca 2 rise in advance of force development. During the prolonged stimulation with PE, the Ca 2 level was partially decreased to 42 8% (n 5) of the transient peak. Figure 1B confirms that the increase in MLC phosphorylation precedes the development of contraction. 16 At 7 seconds, MLC was already phosphorylated to 90% of the peak level ( mol of Pi/mol of MLC at 15 seconds; n 6), whereas the force at the 7-second time point was developed to only 30% of the peak level at 5 minutes. Figure 1C and 1D illustrates a representative immunoblotting image and average extent of phosphorylated CPI-17 at Thr38 or MYPT1 at Thr853 in the PE-stimulated arterial tissues at various time points. CPI-17 was rapidly phosphorylated from a negligible value at rest (0 second in C and D) to a peak at 7 seconds similar to the rate of MLC phosphorylation but much faster than MYPT1 Thr853 phosphorylation and force development. The stoichiometry of CPI-17 phosphorylation was (n 13) at rest and mol of Pi/mol (n 4) of CPI-17 at 7 seconds after PE stimulation. In contrast, MYPT1 Thr853 at resting state was already phosphorylated to a considerable level (43 7% of value at 60 seconds). The phosphorylation was slowly increased similar to the rate at which the contractile force was developed (Figure 1B and 1D). In contrast to MYPT1 Thr853, the phosphorylation of MYPT1 at Thr696 was detected at rest and was not significantly increased at 60 seconds (not shown), confirming the previous results. 8 The stoichiometry of MYPT1 phosphorylation at Thr853 was estimated as mol of Pi/mol (n 13) of MYPT1 at rest and reached mol/mol (n 4) at 60 seconds after PE stimulation. Assuming that the protein content of the typical mammalian cell is 18% of the total cell weight, the total MYPT1 concentration, ie, MLCP

3 Dimopoulos et al Ca 2 -Dependent Ca 2 Sensitization 123 Figure 1. Time courses of Ca 2 signal (A), force development (A and B), and phosphorylation of MLC (B) and CPI-17 and MYPT1 (C and D) in response to 50 mol/l PE in intact rabbit femoral artery at 30 C. A, Representative recording of simultaneous measurements of Fura-2 (F340/F38) ratio signal (red) and force development (black) in the Fura-2 loaded artery. B and D illustrate the average time courses of force and MLC phosphorylation (pmlc), as well as phosphorylation of CPI-17 at Thr38 (pcpi-17) and MYPT1 at Thr853 (pmypt1), respectively (n 4 to 12). Phosphorylation values of CPI-17 or MYPT1 were normalized with a respective value of 1 minute. C, Representative Western blot image for total and phosphorylated MYPT1 and total and phosphorylated CPI-17. PE was added at the time 0. concentration, was mol/l (n 6) in rabbit femoral artery. Total expression level of CPI-17 in rabbit femoral artery is previously estimated 6 1 mol/l 13 ; thereby the cellular concentration of phosphorylated CPI-17 is increased to mol/l at 7 seconds. After 15 seconds of PE stimulation, on the other hand, phosphorylation levels of MLC began to significantly but partially decline from (n 6) to mol of Pi/mol of MLC (n 4) at 60 seconds and then to mol/mol (n 4) at 5 minutes. The phosphorylation level at 5 minutes was still much higher than that at rest, whereas average contraction level was maintained up to 5 minutes (Figure 1B) and thereafter started to decline during PE stimulation in many cases. The phosphorylated CPI-17 level also tended to decline slightly but not significantly to mol/l (n 5) at 5 minutes (Figure 1D), whereas MYPT1 phosphorylation level was not decreased and was maintained up to 5 minutes (Figure 1D; mol/mol; n 7). Effect of Inhibition of Ca 2 Rise on PE-Induced Phosphorylation and Contraction A mixture of 2 Ca 2 blockers (2 mol/l ryanodine, 17 to open-lock the SR Ca 2 release channel plus 1 mol/l nicardipine, 18 to inhibit the voltage-dependent L-type Ca 2 channel) was applied to eliminate the [Ca 2 ] i increase by PE (Figure 2). The blocking of both the SR Ca 2 release and the voltage-dependent Ca 2 influx totally abolished an increase in cytoplasmic Ca 2 in response to PE (Figure 2A). The lack of PE-induced Ca 2 increase strongly inhibited the initial fastrising phase and also the sustained phase of PE-induced contraction (Figure 2B), and MLC phosphorylation at 7 and 15 second-time points (Figure 2C). However, these Ca 2 blockers had no significant effect on MLC phosphorylation at 5 minutes after PE stimulation (Figure 2C) and did not prevent the slow development of contraction (Figure 2B). The basal levels of Ca 2 was slightly elevated possibly because of the leakage of Ca 2 through the ryanodine receptors 17 or an increase in the Ca 2 influx by the depletion of Ca 2 stores. 19 This may cause a slight increase in the resting MLC phosphorylation (0 second in Figure 2C) and force (not shown). The inhibition of the Ca 2 rise almost abolished the rapid increase in PE-induced phosphorylation of CPI-17 at 7 seconds (Figure 2D), whereas the phosphorylation was thereafter significantly increased at 15 seconds and 5 minutes by and mol/l, respectively. In contrast, the MYPT1 phosphorylation in the presence of Ca 2 blockers increased similar to the control in the absence (Figure 2E). To further evaluate the effects of Ca 2 blockers on the initial rapid rising and sustained phases of PE-induced contraction, arterial strips were subjected to an individual blocker, nicardipine or ryanodine alone (Figure 3). Pretreatment with 1 mol/l nicardipine for 10 minutes primarily inhibited the

4 124 Circulation Research January 5/19, 2007 Figure 2. Effect of a mixture of 2 mol/l ryanodine and 1 mol/l nicardipine (Ca 2 blockers) on time course of Ca 2 signal (A), force development (B), and phosphorylation of MLC (C), CPI-17 (D), and MYPT1 (E). Open and hatched bars represent phosphorylation in the absence and presence of inhibitors, respectively. *Significant difference from control under the same time point. The force traces (B) are shown as solid line (mean) with 1 SEM bar. Treatment of arterial strips with ryanodine and nicardipine are described in detail in the online data supplement. sustained but not initial rapid phase of PE-induced contraction (Figure 3A). Longer treatment with the Ca 2 entry blocker for 30 to 40 minutes caused a gradual suppression of both initial and sustained phases of contraction (not shown), possibly because of a depletion of the SR of Ca 2. Ryanodine, in contrast, suppressed the initial rapid-rising phase of PE-induced contraction but had no effect on the sustained phase of the contraction (Figure 3A). The ryanodine treatment diminished the phasic component of Ca 2 rise in response to PE, but the sustained phase of Ca 2 was higher than the control without the treatment (the red trace compared with the black in Figure 3B). The phosphorylation of CPI-17 in response to PE at 7 seconds was completely prevented by the ryanodine treatment (0 0% in Figure 3D) but partially increased at 15 seconds (25 8% for ryanodine treatment versus % for control; n 3). At 5 minutes, CPI-17 became phosphorylated to 58 18% (n 3; Figure 3E), which was not significantly different from the control at 5 minutes. The value was significantly higher than that of the channel blocker combination (Figure 3D). The ryanodine treatment had no significant effect on the PE-induced MYPT1 phosphorylation at 7 seconds and 5 minutes (Figure 3F and 3G). Furthermore, we tested the effects of another 2 Ca 2 blockers on contraction: thapsigargin, an inhibitor for the SR Ca 2 ATPase, 20 and 2-aminoethoxydiphenyl borate (2-APB), an IP 3 receptor antagonist. 21 We confirmed that treatment with 10 mol/l thapsigargin but not with 30 mol/l 2-APB strongly suppressed 20 mmol/l caffeine-induced transient contraction in the absence of Ca 2. Both thapsigargin and 2-APB, like ryanodine, delayed the initial onset of PE-induced contraction (not shown), whereas the latter compound, in contrast to ryanodine and thapsigargin, strongly suppressed the sustained tonic level of the contraction to 24 2% (n 4) of control. The high K -induced membrane depolarization of smooth muscle tissues is known to rapidly increase [Ca 2 ] i through direct opening of the voltage-dependent Ca 2 channels, MLC phosphorylation, and a contraction. 15,16 We examined the effect of high (124 mmol/l) K on the Ca 2 signal and CPI-17 and MYPT1 phosphorylation in the ryanodine-treated strips. Both initial and maintained levels of Ca 2 rise were higher during the high K stimulation than that of PE in rabbit femoral artery (Figure 3C). The high K stimulation of the untreated strips, although producing a rapid increase in contraction, did not have a significant effect on phosphorylation of CPI-17 nor MYPT1 at 7 seconds, as compared with the respective resting value (Figure 3D and 3F). Five minutes of stimulation with high K, however, significantly elevated MYPT1 phosphorylation (Figure 3G), whereas CPI-17 phosphorylation was still not significantly increased (Figure 3E). Simultaneous stimulation with high K

5 Dimopoulos et al Ca 2 -Dependent Ca 2 Sensitization 125 Figure 3. Effect of 2 mol/l ryanodine on time course of force development (A), Ca 2 signal (B), and phosphorylation of CPI-17 (D and E) and MYPT1 (F and G). A, Average time course of force development with PE in the presence of ryanodine or 1 mol/l nicardipine (n 4) as compared with control (n 8). B, Time course of Ca 2 increase by stimulation with PE alone (black), PE in the presence of ryanodine (red), or PE plus high (124 mmol/l) K (blue) in the presence of ryanodine. C, Comparison between the time course of Ca 2 increase induced by high K and PE. D, Phosphorylation of CPI-17 at Thr38 after 7-second stimulation of the ryanodine (Ry)-treated strips with PE, high K, or PE plus high K, compared with the value at rest and of control PE stimulation for 7 seconds. E, Phosphorylation of CPI-17 after 5-minute stimulation under various conditions. F and G, Phosphorylation of MYPT1 after 7-second (F) and 5-minute (G) stimulation, respectively, under various conditions. K indicates 124 mmol/l K. and PE of the ryanodine-treated strips for 7 seconds and 5 minutes raised CPI-17 phosphorylation to a high level (Figure 3D and 3E). In contrast, the PE-induced phosphorylation of MYPT1 in the ryanodine-treated strips was significantly decreased by the addition of high K at 5 minutes (Figure 3G). Effects of PKC Inhibitors on PE-Induced Phosphorylation and Contraction Three modes of PKC inhibitors, GF X (binding to the catalytic domain of both conventional and novel PKCs), 22 calphostin C (binding to the regulatory domain of both conventional and novel PKCs), 23 and Gö6976 (binding to the catalytic domain of conventional PKC) 22 were used to examine the role of PKC in the PE-induced contraction. GF X at 3 mol/l significantly, but slightly, decreased the rate of initial rise in [Ca 2 ] i by PE (Figure 4A) but did not reduce the sustained level of [Ca 2 ] i. The GF compound also inhibited both the initial rising phase and the sustained phase of the PE-induced contraction, with a small delay in the onset (Figure 4C). The delay was much shorter than that caused by the Ca 2 channel blocker combination (Figure 4C versus Figure 2B). Calphostin C (1 mol/l) had a similar inhibitory effect on both initial rising and sustained phases of PEinduced contraction (Figure 4D), but without obvious delay in the Ca 2 signals (Figure 4B). Gö6976 (10 mol/l) had a similar inhibitory effect on the initial rising phase but less effect on the sustained level of the contraction, as compared with those of conventional PKC (cpkc)/novel PKC (npkc) inhibitors (Figure 4E). GF X significantly inhibited the PE-induced increase in MLC phosphorylation at all 3 time points but had no effect at rest (hatched bar at 0 second in Figure 4E). The CPI-17 phosphorylation at 7 seconds after stimulation with PE was almost completely blocked by the presence of GF X, and thereafter slightly increased at 15 seconds and 5 minutes (Figure 4F) similar to the effect of the Ca 2 blocker combination (Figure 4D). Calphostin C at 1 mol/l also significantly inhibited PE-induced CPI-17 phosphorylation to 21 1% (n 3) at 7 seconds, but less effective than 3 mol/l GF X. In contrast, the MYPT1 phosphorylation was not significantly decreased by either GF X (Figure 4G) or calphostin C (62 10% at 7 seconds and 118 6% at 5 minutes; n 3). Effects of Rho-Kinase Inhibitors on PE-Induced Phosphorylation and Contraction We examined the effect of Rho-kinase inhibitors (Y and H ) on PE-induced contraction and phosphorylation. Y (10 mol/l) had a slight inhibitory effect on the initial rising phase of [Ca 2 ] i increase by 50 mol/l PE but not in the sustained phase (Figure 5A), similar to the effect of GF X. Both Y and H-1152 (3 mol/l) inhibited the sustained phase of PE-induced contraction, whereas the inhibitors (even 30 mol/l Y-27632) had almost no effect on the initial rising phase of contraction (Figure 5B and 5C). The effect of the 3 types of inhibitors (Ca 2 blockers, GF X, and Y-27632) on PE-induced contraction were additive in any combination of 2, and the pretreatment with all 3 types of inhibitors totally abolished the development of PE-induced contraction (not shown). Y (10 mol/l) had no significant effect on phosphorylation of MLC and CPI-17 by the 7-second time point after 50 mol/l PE stimulation, and, thereafter, phosphorylation of both proteins were significantly but partially inhibited (Figure 5D and 5E). H-1152 (3 mol/l) also significantly reduced CPI-17 phosphorylation to a level similar to Y (n 3; 30 5% versus 42 7% in Y-27632) at 5 minutes. The MYPT1 phosphorylation at every time point, including rest, was almost abolished by Y (Figure 5F). H-1152 had a similar inhibitory effect on MYPT1 phosphorylation at 5 minutes (n 3; 12 2% versus 15 3% in Y-27632).

6 126 Circulation Research January 5/19, 2007 Figure 4. Effect of 3 mol/l GF X on time course of Ca 2 signal (A), force development (C), and phosphorylation of MLC (F), CPI-17 (G), and MYPT1 (H) during PE-induced contraction. B and D show the effect of 1 mol/l calphostin C on Ca 2 signal and force development, respectively. E, Effect of 10 mol/l Gö6976 on force development in the presence of 1% DMSO with a 30-minute pretreatment because of low solubility of this inhibitor in the physiological salt solutions. Hatched bars in F, G, and H represent values in the presence of GF X. Discussion This study demonstrates unique roles of the phosphorylation of CPI-17 at Thr38 and MYPT1 at Thr853, respectively, in PE-induced contraction of artery. The rapid phosphorylation of CPI-17 in physiological conditions is totally reliant on Ca 2 release from the SR and on Ca 2 -dependent PKC activity, and concomitant with a rapid rise in Ca 2 and an initial rapid development of MLC phosphorylation. On the other hand, the Ca 2 -independent phosphorylation of both CPI-17 and MYPT1 by Rho-kinase occurs in the following sustained phase, in parallel with a force generation. These results indicate the existence of 2 distinct Ca 2 -sensitizing signal transduction pathways, leading to inhibition of MLCP: rapid and slow mechanisms mainly driven by PKC and Rho-kinase, respectively (Figure 6). We propose a hypothesis that the rapid-signaling messenger Ca 2 synchronously increases and decreases MLCK and MLCP, respectively, toward the same target protein to synergistically increase a rapid phosphorylation of MLC and to initiate a rapid development of contraction in artery (left side of signal transduction pathways in Figure 6). Mechanism for Rapid Agonist-Induced Ca 2 Sensitization The initial rapid phosphorylation of CPI-17 was Ca 2 dependent. Treatment of arterial smooth muscle with ryanodine in the presence of caffeine (see the expanded Materials and Methods section in the online data supplement) depleted the SR of Ca 2, and thus abolished the transient component of Ca 2 increase and the initial rapid but not slow increase in phosphorylation of CPI-17 and contraction in response to PE (Figure 3). Total inhibition of Ca 2 rise in response to PE with the mixture of ryanodine and nicardipine abolished the initial rapid and also inhibited the sustained slow components of CPI-17 phosphorylation (Figure 2). Together, these results suggest that the SR Ca 2 release is responsible for the initial rapid phase of CPI-17 phosphorylation and contraction, and the voltage-dependent Ca 2 influx plays a crucial role in the late sustained phase (Figure 6). The membrane depolarization by high K evokes Ca 2 rise, MLC phosphorylation, and smooth muscle contraction, whereas the Ca 2 rise did not trigger the CPI-17 phosphorylation, even though the [Ca 2 ] i level during high K -induced contraction was higher than that of PE (Figure 3). In fact, increase in the [Ca 2 ] i to 1 mol/l

7 Dimopoulos et al Ca 2 -Dependent Ca 2 Sensitization 127 Figure 5. Effect of 10 mol/l Y on time course of Ca 2 signal (A), force development (B), and phosphorylation of MLC (D), CPI-17 (E), and MYPT1 (F) with respective control. C, Effect of 3 mol/l H-1152 on the time course of force development induced by PE. Hatched bars represent values in the presence of Y using the Ca 2 /EGTA buffer in toxin permeabilized strips did not significantly increase CPI-17 phosphorylation. 11 These results, together, suggest that Ca 2 is required but not sufficient for triggering CPI-17 phosphorylation. The rapid CPI-17 phosphorylation by PE was also eliminated by a PKC inhibitor, either GF X or calphostin C, but not by the Rho-kinase inhibitor Y (Figure 4G versus Figure 5E). These results, in conjunction with the fact that both PKC and PKC but not PKC are expressed as major Ca 2 - dependent PKC isoforms in rabbit femoral artery (G. Dimopoulos, T. Kitazawa, unpublished results, 2005), suggest that both IP 3 -induced SR Ca 2 release and DAG-induced activation of Ca 2 -dependent PKC and/or - isoforms are required for the CPI-17 phosphorylation (Figure 6). Removal of rapid CPI-17 phosphorylation by ryanodine treatment (Figure 3D) raises a possibility that Ca 2 release from the SR is specific for the rapid activation of PKC and thus the CPI-17 phosphorylation. However, even after destruction of the SR Ca 2 release by ryanodine treatment, PE with Ca 2 influx by high K was able to induce a rapid phosphorylation of CPI-17 to a level equivalent to control without ryanodine treatment (Figure 3D and 3E). We presume that, under the physiological conditions, PE-induced Ca 2 release but not Ca 2 influx is the mediator for the rapid CPI-17 phosphorylation, possibly because of coordinated timing between Ca 2 release and DAG production. The Ca 2 influx induced by PE appears to be too slow for activation of Ca 2 -dependent cpkc (Figure 3B). This Ca 2 -dependent phosphorylation of CPI-17, together with the activation of MLCK, initiates a rapid increase in MLC phosphorylation and contraction before the slow RhoA/Rho-kinase signaling pathway (Figure 6). Recently, we have demonstrated that chicken smooth muscle tissues lack both CPI-17 expression and 4- -phorbol-12,13-dibutyrate (PDBu)-induced contraction, unlike pigeon or other mammals. 26 We found that the rise of PE-induced contraction in CPI-17 deficient chicken mesenteric artery was much slower than those of CPI-17 rich rabbit and pigeon arteries (also see Kitazawa et al 26 ). These data support the hypothesis that CPI-17 is necessary for the rapid contraction induced on agonist stimulation in artery. Rapid Phosphorylation of CPI-17 and Classical Ca 2 Sensitization In toxin permeabilized smooth muscle, PDBu, GTP S, and histamine rather slowly increase phosphorylation of CPI-17 and MLC, as well as contraction at resting or near resting Ca 2. 1,7,8,14 The steady-state CPI-17 phosphorylation in permeabilized tissues is more strongly inhibited by GF X than Gö6976 or Y-27632, suggesting that a major kinase is Ca 2 -independent npkc. 9 In contrast, this study clearly shows that Ca 2 increase has a crucial role in the rapid phosphorylation of CPI-17 by Ca 2 -dependent cpkc in intact tissues (Figures 3 and 6). This rapid Ca 2 -dependent CPI-17 phosphorylation cannot be seen in permeabilized smooth muscle tissues, where the SR is depleted of Ca 2 and/or Ca 2 is clamped with a high Ca 2 /EGTA buffer. Any treatments modulating the Ca 2 release and/or Ca 2 loading of SR must affect the rapid CPI-17 phosphorylation and, thus, the rapid Ca 2 sensitization of contraction in intact smooth muscle. The Ca 2 -dependent translocation of PKC isoform from the cytosol to the cell surface has been shown in response to

8 128 Circulation Research January 5/19, 2007 Figure 6. Schematic diagram of signal transduction pathways from receptor activation to phosphorylation of myosin and contraction in arterial smooth muscle. The left signaling pathways from activation of the G q G protein coupled receptor toward phosphorylation of myosin are Ca 2 dependent and initiate a rapid development of contraction. In contrast, the right signaling pathways originate mainly from G 12/13 G protein coupled receptor activation, are mostly Ca 2 independent, and support the tonic component of smooth muscle contraction. CaM indicates Ca 2 /calmodulin. PE in smooth muscle cells isolated from ferret portal vein. 27 If the translocation of Ca 2 -dependent PKC is required for the enzymatic activation, CPI-17 should be translocated to the surface membrane. However, the PKC translocation appears a slow process with a half-time of approximately 3 minutes and dependent on a steady-state Ca 2 level but not on an initial large transient of Ca 2, 27 suggesting that the phosphorylation of CPI-17 occurs in advance of the translocation of PKC. The issue, however, should be reevaluated in the fresh smooth muscle tissues or cells under conditions in which CPI-17 is rapidly phosphorylated by PKC in response to agonists. Mechanisms for Slow Phase of Ca 2 Sensitization The sustained tonic level of PE-induced contraction was more strongly inhibited by GF X and calphostin C than Gö6976 (Figure 4E), indicating that Ca 2 -independent npkc takes the place of Ca 2 -dependent cpkc in terms of CPI-17 phosphorylation with time. Phosphorylation of CPI-17 at the slow and sustained phase also contains a small but significant component insensitive to the Ca 2 blockers and PKC inhibitors, as compared with that of the initial phase (Figures 2D and 4G), suggesting that Ca 2 -independent protein kinase(s) rather than PKC is involved in the slow phosphorylation of CPI-17 and the sustained tonic component of contraction. Furthermore, the MLC phosphorylation in the sustained tonic phase of contraction was also insensitive to the Ca 2 blockers or PKC inhibitors, compared with that of the initial phase (Figures 2C and 4F), suggesting that a mechanism(s) other than Ca 2 -dependent PKC/CPI-17 phosphorylation is slowly developed at the late phase. MYPT1 phosphorylation at Thr853 in response to either PE or high K is rather slowly augmented (Figures 1C and 3G) compared with the rapid phosphorylation of MLC and CPI-17. Both Y and H-1152 almost completely abolished this MYPT1 phosphorylation, whereas they did not attenuate the early phase of phosphorylation of MLC and CPI-17 and contraction (Figure 5). Therefore, the regulation of MLCP activity through Rho-kinase is involved in rather late sustained phase but not the early phase of PE-induced MLC phosphorylation and contraction. This is consistent with the observation that noradrenalin stimulation induces a slow increase in the amount of active GTP-bound form of RhoA in aorta 28 and that photolysis of caged GTP-G14V RhoA/GDI complex in permeabilized portal vein induces a slow onset of contraction, 1 similar to the time course of the MYPT1 Thr853 phosphorylation (Figure 1). On the other hand, when both Ca 2 release and Ca 2 influx were blocked with Ca 2 blockers, MLC phosphorylation and contraction were still significantly and slowly increased under the conditions in which MLCK was supposedly not increased (Figure 2). This contraction was partially inhibited by either GF X or Y and completely inhibited by a mixture of 2 inhibitors (not shown). These results suggest that this slow development of MLC phosphorylation indicates a slow inhibi-

9 Dimopoulos et al Ca 2 -Dependent Ca 2 Sensitization 129 tion of MLCP in intact artery via 3 possible Ca 2 -independent mechanisms: npkc/cpi-17, Rho-kinase/CPI-17, and Rhokinase/MYPT1 (Figure 6). In conclusion, 1 agonist triggers the Ca 2 release from the SR to induce a rapid and Ca 2 -dependent phosphorylation of the MLCP inhibitor protein CPI-17 in artery. This can lead to a dual regulation of MLC phosphorylation in a synchronous way (Figure 6): a downregulation of phosphatase in coordination with the upregulation of Ca 2 -dependent kinase to synergistically increase a phosphorylation of the same target protein MLC and a large contraction with a small increase in Ca 2. The expression level of CPI-17, however, greatly varies with smooth muscle tissue types 13 ; therefore, this rapid CPI-17 signaling appears to be vital in vascular smooth muscles, although insignificant in visceral phasic smooth muscles. Sources of Funding This work was supported by NIH grants R01HL70881 and P01AR (to T.K.) and R01HL (to M.E.). None. Disclosures References 1. Somlyo AP, Somlyo AV. Ca 2 sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83: Wier WG, Morgan KG. 1 -Adrenergic signaling mechanisms in contraction of resistance arteries. Rev Physiol Biochem Pharmacol. 2003; 150: Isotani E, Zhi G, Lau KS, Huang J, Mizuno Y, Persechini A, Geguchadze R, Kamm KE, Stull JT. Real-time evaluation of myosin light chain kinase activation in smooth muscle tissues from a transgenic calmodulinbiosensor mouse. Proc Natl Acad Sci U S A. 2004;101: Hartshorne DJ, Ito M, Erdodi F. Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil. 1998; 19: Murányi A, Derkach D, Erdődi F, Kiss A, Ito M, Hartshorne DJ. Phosphorylation of Thr695 and Thr850 on the myosin phosphatase target subunit: inhibitory effects and occurrence in A7r5 cells. FEBS Lett. 2005;579: Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, Nakano T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem. 1999;274: Kitazawa T, Eto M, Woodsome TP, Khalequzzaman M. Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca 2 sensitization in rabbit smooth muscle. J Physiol. 2003;546: Niiro N, Koga Y, Ikebe M. Agonist-induced changes in the phosphorylation of the myosin binding subunit of myosin light chain phosphatase and CPI17, two regulatory factors of myosin light chain phosphatase, in smooth muscle. Biochem J. 2003;369: Eto M, Kitazawa T, Yazawa M, Mukai H, Ono Y, Brautigan D. Histamine-induced vasoconstriction involves phosphorylation of a specific inhibitor protein for myosin phosphatase by protein kinase C and isoforms. J Biol Chem. 2001;276: Hayashi Y, Senba S, Yazawa M, Brautigan DL, Eto M. Defining the structural determinants and a potential mechanism for inhibition of myosin phosphatase by the protein kinase C-potentiated inhibitor protein of 17 kda. J Biol Chem. 2001;276: Kitazawa T, Eto M, Woodsome TP, Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem. 2000;275: Pang H, Guo Z, Su W, Xie Z, Eto M, Gong MC. RhoA-Rho kinase pathway mediates thrombin- and U induced phosphorylation of a myosin phosphatase inhibitor, CPI-17, in vascular smooth muscle cells. Am J Physiol. 2005;289:C352 C Woodsome TP, Eto M, Everett A, Brautigan DL, Kitazawa T. Expression of CPI-17 and myosin phosphatase correlates with Ca 2 sensitivity of protein kinase C-induced contraction in rabbit smooth muscle. J Physiol. 2001;535: Masuo M, Reardon S, Ikebe M, Kitazawa T. A novel mechanism for the Ca 2 -sensitizing effect of protein kinase C on vascular smooth muscle: inhibition of myosin light chain phosphatase. J Gen Physiol. 1994;104: Himpens B, Kitazawa T, Somlyo AP. Agonist-dependent modulation of Ca 2 -sensitivity in rabbit pulmonary artery smooth muscle. Pflugers Arch. 1990;417: Hai C-M, Murphy RA. Ca 2, crossbridge phosphorylation, and contraction. Ann Rev Physiol. 1989;51: Meissner G. Ryanodine activation and inhibition of the Ca 2 release channel of sarcoplasmic reticulum. J Biol Chem. 1986;261: Nakazawa K, Saito H, Matsuki N. Fast and slowly inactivating components of Ca-channel current and their sensitivities to nicardipine in isolated smooth muscle cells from rat vas deferens. Pflugers Archiv. 1988;411: Berridge MJ. Capacitative calcium entry. Biochem J. 1995;312: Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca 2 stores by specific inhibition of the endoplasmic reticulum Ca 2 -ATPase. Proc Natl Acad USA. 1990;87: Ascher-Landsberg J, Saunders T, Elovitz M, Phillippe M. The effects of 2-aminoethoxydiphenyl borate, a novel inositol 1,4, 5- trisphosphate receptor modulator on myometrial contractions. Biochem Biophys Res Commun. 1999;264: Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, Duhamel L, Charon D, Kirilovsky J. The bisindolylmaleimide GF X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266: Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN- 1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1989;159: Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389: Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-( )-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]- homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93: Kitazawa K, Polzin A, Eto M. CPI-17-deficient smooth muscle of chicken. J Physiol. 2004;557: Khalil RA, Lajoie C, Morgan KG. In situ determination of [Ca 2 ]i threshold for translocation of the -protein kinase C isoform. Am J Physiol. 1994;266:C1544 C Sakurada S, Takuwa N, Sugimoto N, Wang Y, Seto M, Sasaki Y, Takuwa Y. Ca 2 -dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res. 2003;93: